{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T22:13:01Z","timestamp":1793743981621,"version":"4.6.1"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T00:00:00Z","timestamp":1714694400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background and Aims<\/jats:title>\n                  <jats:p>Infections are a safety concern in patients with ulcerative colitis [UC]. Etrasimod is an oral, once daily [QD], selective sphingosine 1-phosphate [S1P]1,4,5 receptor modulator for the treatment of moderately to severely active UC. It leads to selective and reversible lymphocyte sequestration and partial peripheral lymphocyte count decrease. We report infection events from the phase 3 ELEVATE programme.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Proportions, incidence rates [IRs; per 100 patient-years], and descriptive analyses of all serious, severe, herpes zoster and opportunistic infections are reported in the Pivotal UC cohort [ELEVATE UC 52 and ELEVATE UC 12]. Cox regression models evaluated potential baseline risk factors.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In this analysis [n\u2005=\u2005787], proportions [IRs] of all infection events were similar for patients receiving etrasimod 2 mg QD (18.8% [41.1]) or placebo (17.7% [49.0]). Serious infections occurred in three [0.6%] and five [1.9%] patients receiving etrasimod and placebo, respectively. Two herpes zoster events were reported in each group [etrasimod: 0.4%; placebo: 0.8%], all localised and non-serious. One opportunistic infection event was reported in each group. No patient with an absolute lymphocyte count [ALC]\u2005&amp;lt;\u20050.2\u2005\u00d7\u2005109\/L reported serious\/severe or opportunistic infections; no baseline risk factors were identified for such events. No deaths occurred.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Patients receiving etrasimod demonstrated no increased risk of infection. The incidence of serious infections and herpes zoster was similar in each group. Among patients receiving etrasimod, no association between ALC\u2005&amp;lt;\u20050.5\u2005\u00d7\u2005109\/L and infection events was observed. Longer-term follow-up will further characterise the etrasimod safety profile.<\/jats:p>\n                  <jats:p>Clinicaltrials.gov: NCT03945188; NCT03996369<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ecco-jcc\/jjae060","type":"journal-article","created":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T10:33:35Z","timestamp":1714732415000},"page":"1596-1605","source":"Crossref","is-referenced-by-count":26,"title":["Etrasimod for the Treatment of Ulcerative Colitis: Analysis of Infection Events from the ELEVATE UC Clinical Programme"],"prefix":"10.1093","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7681-8111","authenticated-orcid":false,"given":"Miguel","family":"Regueiro","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Hepatology, and Nutrition, Cleveland Clinic , Cleveland, OH ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0055-958X","authenticated-orcid":false,"given":"Britta","family":"Siegmund","sequence":"additional","affiliation":[{"name":"Medizinische Klinik f\u00fcr Gastroenterologie, Infektiologie, Rheumatologie, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin , Berlin ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres J","family":"Yarur","sequence":"additional","affiliation":[{"name":"Inflammatory Bowel Disease Center and Division of Gastroenterology and Hepatology, Cedars-Sinai Medical Center , Los Angeles, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1002-9766","authenticated-orcid":false,"given":"Flavio","family":"Steinwurz","sequence":"additional","affiliation":[{"name":"Unit of Inflammatory Bowel Disease, Hospital Israelita Albert Einstein , S\u00e3o Paulo ,","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4830-142X","authenticated-orcid":false,"given":"Krisztina B","family":"Gecse","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Amsterdam University Medical Center , Amsterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Goetsch","sequence":"additional","affiliation":[{"name":"Pfizer AG , Z\u00fcrich ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Bhattacharjee","sequence":"additional","affiliation":[{"name":"Pfizer Healthcare India Pvt Ltd. , Chennai ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Wu","sequence":"additional","affiliation":[{"name":"Pfizer Inc , Cambridge, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse","family":"Green","sequence":"additional","affiliation":[{"name":"Pfizer Inc , C ollegeville, PA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aoibhinn","family":"McDonnell","sequence":"additional","affiliation":[{"name":"Pfizer Ltd, Sandwich , Kent ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Crosby","sequence":"additional","affiliation":[{"name":"Pfizer Inc , La Jolla, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krisztina","family":"Lazin","sequence":"additional","affiliation":[{"name":"Pfizer AG , Z\u00fcrich ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diogo","family":"Branquinho","sequence":"additional","affiliation":[{"name":"Pfizer Inc , Ne w York, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Modesto","sequence":"additional","affiliation":[{"name":"Pfizer Inc , Ne w York, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria T","family":"Abreu","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Gastroenterology, Crohn\u2019s and Colitis Center, University of Miami Miller School of Medicine , Miami, FL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,5,3]]},"reference":[{"key":"2024101600035562700_CIT0001","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(16)32126-2","article-title":"Ulcerative colitis","volume":"389","author":"Ungaro","year":"2017","journal-title":"Lancet"},{"key":"2024101600035562700_CIT0002","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1097\/MIB.0000000000000080","article-title":"Fibrosis in ulcerative colitis: mechanisms, features, and consequences of a neglected problem","volume":"20","author":"Gordon","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"2024101600035562700_CIT0003","first-page":"CD000544","article-title":"Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis","volume":"8","author":"Murray","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"2024101600035562700_CIT0004","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s12876-017-0602-0","article-title":"Inflammatory Bowel Disease [IBD] pharmacotherapy and the risk of serious infection: a systematic review and network meta-analysis","volume":"17","author":"Wheat","year":"2017","journal-title":"BMC Gastroenterol"},{"key":"2024101600035562700_CIT0005","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/ecco-jcc\/jjab052","article-title":"ECCO guidelines on the prevention, diagnosis, and management of infections in inflammatory bowel disease","volume":"15","author":"Kucharzik","year":"2021","journal-title":"J Crohns Colitis"},{"key":"2024101600035562700_CIT0006","doi-asserted-by":"crossref","first-page":"7140","DOI":"10.1038\/s41598-022-10777-w","article-title":"Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database","volume":"12","author":"Hoisnard","year":"2022","journal-title":"Sci Rep"},{"key":"2024101600035562700_CIT0007","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1093\/ecco-jcc\/jjac145","article-title":"What are the unmet needs and most relevant treatment outcomes according to patients with inflammatory bowel disease? A qualitative patient preference study","volume":"17","author":"Schoefs","year":"2023","journal-title":"J Crohns Colitis"},{"key":"2024101600035562700_CIT0008","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S0140-6736(23)00061-2","article-title":"Etrasimod as induction and maintenance therapy for ulcerative colitis [ELEVATE]: two randomised, double-blind, placebo-controlled, phase 3 studies","volume":"401","author":"Sandborn","year":"2023","journal-title":"Lancet"},{"key":"2024101600035562700_CIT0009","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/cpdd.1255","article-title":"Disposition and mass balance of etrasimod in healthy subjects and in vitro determination of the enzymes responsible for its oxidative metabolism","volume":"12","author":"Lee","year":"2023","journal-title":"Clin Pharmacol Drug Dev"},{"key":"2024101600035562700_CIT0010","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.crohns.2013.12.013","article-title":"Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease","volume":"8","author":"Rahier","year":"2014","journal-title":"J Crohns Colitis"},{"key":"2024101600035562700_CIT0011","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.cgh.2020.12.030","article-title":"Risk of serious infections with vedolizumab versus tumor necrosis factor antagonists in patients with inflammatory bowel disease","volume":"20","author":"Kirchgesner","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2024101600035562700_CIT0012","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1136\/flgastro-2019-101288","article-title":"Steroid use and misuse: a key performance indicator in the management of IBD","volume":"12","author":"Blackwell","year":"2021","journal-title":"Frontline Gastroenterol"},{"key":"2024101600035562700_CIT0013","doi-asserted-by":"crossref","first-page":"e0158017","DOI":"10.1371\/journal.pone.0158017","article-title":"Corticosteroid use and complications in a US inflammatory bowel disease cohort","volume":"11","author":"Waljee","year":"2016","journal-title":"PLoS One"},{"key":"2024101600035562700_CIT0014","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.14309\/01.ajg.0000722976.59079.27","article-title":"P045 Effect of etrasimod on circulating lymphocyte subsets: data from a randomized phase 1 study in healthy Japanese and Caucasian men","volume":"115","author":"Komori","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"2024101600035562700_CIT0015","doi-asserted-by":"crossref","first-page":"e673","DOI":"10.14309\/01.ajg.0000860352.29232.aa","article-title":"S928 Effect of etrasimod on circulating lymphocytes in patients with moderately to severely active ulcerative colitis: data from the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials","volume":"117","author":"Danese","year":"2022","journal-title":"Am J Gastroenterol"},{"key":"2024101600035562700_CIT0016","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1124\/dmd.120.000220","article-title":"Absorption, metabolism, and excretion, in vitro pharmacology, and clinical pharmacokinetics of ozanimod, a novel sphingosine 1-phosphate receptor modulator","volume":"49","author":"Surapaneni","year":"2021","journal-title":"Drug Metab Dispos"},{"key":"2024101600035562700_CIT0017","first-page":"S60","article-title":"P-179 Safety, pharmacokinetics and pharmacodynamics of etrasimod [APD334], an oral selective S1P receptor modulator, after dose-escalation, in healthy volunteers [abstract P-179]","volume":"23","author":"Peyrin-Biroulet","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"2024101600035562700_CIT0018","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s40264-021-01057-z","article-title":"Safety of S1P modulators in patients with immune-mediated diseases: a systematic review and meta-analysis","volume":"44","author":"Lasa","year":"2021","journal-title":"Drug Saf"},{"key":"2024101600035562700_CIT0019","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1056\/NEJMoa2033617","article-title":"Ozanimod as induction and maintenance therapy for ulcerative colitis","volume":"385","author":"Sandborn","year":"2021","journal-title":"N Engl J Med"},{"key":"2024101600035562700_CIT0020","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1056\/NEJMoa1513248","article-title":"Ozanimod induction and maintenance treatment for ulcerative colitis","volume":"374","author":"Sandborn","year":"2016","journal-title":"N Engl J Med"},{"key":"2024101600035562700_CIT0021","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1053\/j.gastro.2020.01.001","article-title":"Safety of Janus kinase inhibitors in patients with inflammatory bowel diseases or other immune-mediated diseases: a systematic review and meta-analysis","volume":"158","author":"Olivera","year":"2020","journal-title":"Gastroenterology"},{"key":"2024101600035562700_CIT0022","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N Engl J Med"},{"key":"2024101600035562700_CIT0023","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1093\/ecco-jcc\/jjac133","article-title":"Opportunistic infections in patients with inflammatory bowel disease treated with advanced therapies: a systematic review and meta-analysis of randomized controlled trials","volume":"17","author":"Olivera","year":"2023","journal-title":"J Crohns Colitis"},{"key":"2024101600035562700_CIT0024","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1093\/ibd\/izy153","article-title":"Low frequency of opportunistic infections in patients receiving vedolizumab in clinical trials and post-marketing setting","volume":"24","author":"Ng","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"2024101600035562700_CIT0025","doi-asserted-by":"crossref","first-page":"i619","DOI":"10.1093\/ecco-jcc\/jjac190.0620","article-title":"P490 Etrasimod for the treatment of ulcerative colitis: up to 2.5 years of pooled safety data from global clinical trials [abstract P490]","volume":"17","author":"Vermeire","year":"2023","journal-title":"J Crohns Colitis"},{"key":"2024101600035562700_CIT0026","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.7326\/M22-1460","article-title":"Good Publication Practice [GPP] guidelines for company-sponsored biomedical research: 2022 update","volume":"175","author":"DeTora","year":"2022","journal-title":"Ann Intern Med"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/advance-article-pdf\/doi\/10.1093\/ecco-jcc\/jjae060\/57677926\/jjae060.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/18\/10\/1596\/59765653\/jjae060.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/18\/10\/1596\/59765653\/jjae060.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T00:04:14Z","timestamp":1729037054000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/18\/10\/1596\/7663764"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,3]]},"references-count":26,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,5,3]]},"published-print":{"date-parts":[[2024,10,15]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjae060","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,10]]},"published":{"date-parts":[[2024,5,3]]}}}